Validation of the IBIS breast cancer risk evaluator for women with lobular carcinoma in-situ.
Br J Cancer
; 119(1): 36-39, 2018 07.
Article
em En
| MEDLINE
| ID: mdl-29925933
ABSTRACT
BACKGROUND:
Management advice for women with lobular carcinoma in situ (LCIS) is hampered by the lack of accurate personalised risk estimates for subsequent invasive breast cancer (BC). Prospective validation of the only tool that estimates individual BC risk for a woman with LCIS, the International Breast Cancer Intervention Study Risk Evaluation Tool (IBIS-RET), is lacking.METHODS:
Using population-based cancer registry data for 732 women with LCIS, the calibration and discrimination accuracy of IBIS-RET Version 7.2 were assessed.RESULTS:
The mean observed 10-year risk of invasive BC was 14.1% (95% CI11.3%-17.5%). IBIS-RET overestimated invasive BC risk (p = 0.0003) and demonstrated poor discriminatory accuracy (AUC 0.54, 95% CI 0.48 - 0.62).CONCLUSIONS:
Clinicians should understand that IBIS-RET Version 7.2 may overestimate 10-year invasive BC risk for Australian women with LCIS. The newer IBIS-RET Version 8.0, released September 2017, includes mammographic density and may perform better, but validation is needed.
Texto completo:
1
Coleções:
01-internacional
Temas:
Epidemiologia
/
Geral
/
Saude_da_mulher
/
Mama
/
Tipos_de_cancer
/
Mama
/
Outros_tipos
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
/
Carcinoma de Mama in situ
/
Invasividade Neoplásica
Tipo de estudo:
Etiology_studies
/
Risk_factors_studies
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
País/Região como assunto:
Oceania
Idioma:
En
Revista:
Br J Cancer
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
Austrália